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ABSTRACT
Introduction: Metformin is the recommended
initial treatment in type 2 diabetes mellitus
(T2DM), but when this does not give adequate
glucose control the choice of which second-line
drug to use is uncertain as none have been
found to have a better overall glycaemic
response. In this real-world study dipeptidyl
peptidase 4 inhibitors (DPP4i), sulphonylureas
(SU), thiazolidinediones (TZD) and sodium
glucose co-transporter 2 inhibitors (SGLT2i)
were compared for their effectiveness in lower-
ing glycated haemoglobin (HbA1c) levels for a
particular individual based on their clinical
characteristics.
Methods: A retrospective analysis was under-
taken of electronic health records of people
with T2DM prescribed metformin alongside a
DPP4i, SU, TZD or SGLT2i at second-line.
Regression modelling was used to model the
changes in HbA1c from baseline at month 6 and
month 12 for the individual therapies, adjust-
ing for demographic and clinical characteristics.
Results: There were 7170 people included in
the study. Treatment at second-line with SUs,
DPP4i, TZDs and SGLT2i resulted in similar
percentages of people achieving the recom-
mended HbA1c target of\7.5%
(58 mmol/mol) at both 6 and 12 months. For
those receiving SGLT2i and SUs, the greatest
improvement in HbA1c was observed in rela-
tively younger and older people, respectively.
Trends were detected between other baseline
characteristics and HbA1c improvement by
drug class, but they were not statistically sig-
nificant. Non-adherence rates were low for all
drug classes. People with a higher medication
possession ratio (C 80%) also had greater
improvements in HbA1c at 12 months.
Conclusion: This study identified patients’
phenotypic characteristics that may have the
potential to influence individual treatment
response. Accounting for these characteristics in
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clinical treatment decisions may facilitate indi-
vidualised prescribing by being able to select the
right drug for the right patient.
Keywords: Dipeptidyl peptidase 4 inhibitor;
Glycaemic control; Second-line therapy;
Sodium-glucose transporter 2 inhibitor;
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Key Summary Points
Why carry out this study?
Metformin is the recommended initial
treatment in type 2 diabetes mellitus
(T2DM), and when this does not give
adequate glucose control the American
Diabetes Association (ADA) and the
European Association for the Study of
Diabetes (EASD) guidelines provide
second-line therapy recommendations
based on the presence of established
chronic kidney disease, heart failure or
atherosclerotic cardiovascular disease.
The majority of people with T2DM do not
have these comorbidities, and for these
people there is uncertainty within the
clinical community around the optimal
choice of second-line treatment, as none
have been found to have a better overall
glycaemic response.
In this study, the real-world efficacy
profiles of dipeptidyl peptidase 4
inhibitors (DPP4i), sulphonylureas (SU),
thiazolidinediones (TZD) and sodium
glucose co-transporter 2 inhibitors
(SGLT2i) following metformin
monotherapy were examined in terms of
glycaemic control as a function of baseline
phenotypic characteristics at second-line
initiation.
What was learned from the study?
The study found little difference in the
glycaemic effects of the different drug
classes at 6 and 12 months.
However, patients’ age may have the
potential to influence treatment response.
In addition, other phenotypic
characteristics such as gender, body mass
index, estimated glomerular filtration rate
(eGFR) and duration of T2DM may also be
associated with HbA1c response but
further research is required to examine
these trends.
Accounting for specific demographic and
clinical characteristics in clinical
treatment decisions will enable better
targeting of second-line regimens
according to a person’s individual profile
to achieve optimal clinical outcomes.
INTRODUCTION
Type 2 diabetes (T2DM) is characterised by
insulin resistance, progressive decline in b-cell
function and associated hyperglycaemia. Gly-
cated haemoglobin (HbA1c) remains the gold
standard for monitoring glycaemic control,
albeit with the limitations that it only measures
average glucose concentration and cannot
report glycaemic excursions or frequency of
hypoglycaemia [1]. Recent cardiovascular out-
come trials (CVOTs) have focused on
macrovascular complications in later diabetes;
however, microvascular complications, present
in approximately 54% of the total population
with diabetes [2], also represent a significant
clinical burden [3]. Microvascular complica-
tions such as blindness, renal failure and dia-
betic foot disease are associated with poor
quality of life [4] and are amongst the greatest
concerns for people with T2DM [5–7]. Opti-
mised glycaemic control to the recommended
HbA1c target of 7% (53 mmol/mol) [8, 9]
remains the optimum strategy for minimising
the risk of these microvascular complications as
well as limiting progression of some macrovas-
cular complications (notably stroke, congestive
heart failure, peripheral vascular disease)
[10–12].
Large randomised trials and prospective
observational studies have demonstrated that
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the level of achieved glycaemic control, rather
than the agent used, is the predictor of inci-
dence and delayed progression of microvascular
complications in early T2DM [12–17]. There are
an increasing number of effective oral hypo-
glycaemic agents (OHAs) for improving gly-
caemic control in T2DM. It is widely accepted
that most people with T2DM should receive
metformin at first line because of its efficacy in
reducing plasma glucose without increasing the
risks of hypoglycaemia or weight gain [18, 19].
When metformin monotherapy fails to achieve
glycaemic control, or the disease progresses
such that glycaemia rises, a second drug will
need to be added to metformin [8, 9]. The most
recent consensus report by the American Dia-
betes Association (ADA) and the European
Association for the Study of Diabetes (EASD)
includes therapy recommendations based on
the presence of comorbidities. These guidelines
recommend the addition of a sodium glucose
co-transporter 2 inhibitor (SGLT2i) or glucagon-
like peptide-1 (GLP1) receptor antagonist fol-
lowing metformin monotherapy, irrespective of
HbA1c level, in people with established chronic
kidney disease (CKD), heart failure (HF) or
atherosclerotic cardiovascular disease (ACVD)
[20]. However, the majority of people with
T2DM do not have these comorbidities. For
these people, given that CVOTs have failed to
show significant benefits in major adverse car-
diovascular events (MACE) with any specific
OHA [21–24], there is uncertainty within the
clinical community around the optimal choice
of second-line drug. Current National Institute
for Health and Care Excellence (NICE) clinical
guidelines recommend that treatment should
be intensified if HbA1c rises to 7.5%
(58 mmol/mol) or higher with metformin
monotherapy [8]. In these cases, metformin
should be combined with a drug from one of
four drug classes: a sulphonylurea (SU), thiazo-
lidinedione (TZD), dipeptidyl peptidase 4 inhi-
bitor (DPP4i) or SGLT2i [8]. However, the
guidelines do not indicate which drug should
be prescribed over other drugs for individuals
according to their unique demographic and
clinical profiles. Instead, the guidelines recom-
mend that treatment decisions be based on
factors such as efficacy, safety, tolerability,
individual clinical circumstances, preferences
and needs, available licensed indications and
cost [8]. If more than one drug in the same class
is suitable, the drug with the lowest acquisition
cost should be prescribed [8].
Meta-analyses comparing the effectiveness of
the different drug classes have demonstrated
similar clinically meaningful reductions in
HbA1c for all classes of second-line drugs when
they are added to metformin as dual therapy,
but with differences in weight gain and risk of
hypoglycaemia [25–27]. However, the real-
world effectiveness of these drugs in routine
clinical practice is less well understood. The
purpose of this study was to explore the real-
world efficacy profiles of OHAs following met-
formin monotherapy in terms of glycaemic
control as a function of baseline phenotypic
characteristics. By using data collected from
routine primary care practice, the study will
generate valuable evidence that is currently
lacking to inform clinical decision making on
the management of people with T2DM who
have failed metformin monotherapy. A better
understanding of patient profiles and treatment
practices may lead to improved disease man-
agement through better targeting of second-line
regimens according to demographic and clinical
characteristics to achieve optimal clinical
outcomes.
METHODS
Study Design
This was a retrospective cohort study using data
obtained from the Clinical Practice Research
Datalink (CPRD) GOLD database [28], which
contains electronic health records of approxi-
mately 11.3 million patients (4.4 million active)
across 674 primary care practices in the UK. The
study data set consisted of adult patients
(C 18 years) diagnosed with T2DM (diagnosis
defined as the presence of a Read code specific
to T2DM in the patient records). Patients were
eligible for study inclusion if they were pre-
scribed metformin as first-line treatment for
T2DM and subsequently received a SU, DPP4i,
TZD or SGLT2i at second-line (as dual therapy
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in combination with metformin). Relevant
prescription records were identified for each
patient by examining British National Formu-
lary (BNF) codes for anti-diabetic drugs.
The index date for each person was the date
of first prescription of the second-line regimen.
Data were extracted for the period between 1
January 2002 and 31 December 2017, with a
study index period between 1 January 2012 and
31 December 2016. People were followed up to
the earliest of death, end of study, 2-year post
index or loss to follow-up (LTFU). LTFU was
defined as the earliest of person transferred out
of GP practice, practice left CPRD or last recor-
ded measurement.
This was a retrospective observational study
using anonymised data from CPRD, which
holds ethical approval for observational studies.
The Independent Scientific Advisory Commit-
tee for Medicines and Healthcare Products
Regulatory Agency approved this study
(19_078RAR). Subsequent amendments were
approved by ISAC on 18 March 2020 (ISAC
protocol reference 19_078RAR).
Study Population
In this study, people were diagnosed with
T2DM between 1 January 2002 and 31 Decem-
ber 2016 and were initially prescribed met-
formin. They subsequently had the addition of
a SU, DPP4i, TZD or SGLT2i between 1 January
2012 and 31 December 2016. Individuals were
required to be on a stable dose of metformin for
at least 3 months prior to intensification to dual
therapy and first prescribed a SU, DPP4i, TZD or
SGLT2i at least 12 months prior to data cut-off.
People previously (prior to T2DM diagnosis)
treated with any antidiabetic medication other
than metformin, with pre-existing ACVD (heart
failure, ischaemic heart disease, peripheral
artery disease, stroke, myocardial infarction,
transient ischaemic attack, coronary artery
stenosis or angina, for whom guidelines would
suggest SGLT2i and/or GLP1 receptor agonists
should be the treatment of choice),
aged\18 years on T2DM diagnosis date, with-
out a HbA1c measurement at baseline or with
HbA1c[ 10% at baseline, or with \ 1 year of
follow-up after dual therapy initiation were
excluded from the study.
Study Outcomes
HbA1c change from baseline was the primary
study outcome. Additional study outcomes
included rates of discontinuation (treatment
switch/cessation) and treatment intensification
(addition of a new drug to second-line dual
therapy) at 6 and 12 months post-baseline, rates
of incident adverse events (AEs) during the
study period at 12 months post-baseline and
medication possession ratio (MPR) across sec-
ond-line drugs (calculated as the number of
days of prescription coverage [quantity of
dosage prescribed divided by the daily dose]
divided by the length of the follow-up period).
Adherence was defined as an MPR C 80%;
individuals with an MPR\ 20% were excluded
[29, 30].
Statistical Analysis
Summary descriptive statistics were calculated
for the overall study population and stratified
by baseline HbA1c. These statistics characterised
demographic, clinical and treatment character-
istics, and medication use. Missing values at
baseline were recorded as such for each variable.
Regression modelling was used to model the
changes in HbA1c at month 6 and month 12 for
each of the individual therapies. Initial 6- and
12-month models were fitted to the full data
with backwards stepwise regression used for
variable selection. This ensured each therapy
model was adjusting for a consistent set of
characteristics. The extent of missingness in
each variable was reviewed to inform decisions
about variable inclusion in the models. Vari-
ables with[40% missingness were excluded
from the modelling process. Baseline HbA1c
was included in as a covariate in each of the
models. Models were fitted to the data to adjust
for the effect of observed covariates (potential
confounders) including demographic charac-
teristics, clinical factors, concomitant prescrip-
tions and comorbidities.
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To explore the factors associated with
change in HbA1c in unadjusted analyses, the
change was grouped into equal tertiles which
represent the people with the smallest drop in
HbA1c, medium size drop in HbA1c and the
greatest drop in HbA1c. The mean and 95%
confidence intervals (CI) of change for each
factor were calculated within each tertile to
show the differences in characteristics for dif-
ferent levels of change. Adverse event rates were
calculated for each second-line therapy. Only
the first event of each type and person time up
to that event per person contributed to the
calculations of the event rates. All analyses were
performed using R version 3.4 or later.
RESULTS
Baseline Demographic and Clinical
Characteristics
In this study, we identified 7170 people with
T2DM in the CPRD data set who received first-
line metformin monotherapy and were subse-
quently initiated on second-line treatment and
who met the study inclusion criteria (Figure S1).
The baseline characteristics of the people
included in analyses are shown in Table 1.
Overall, 59.69% of people were male, the mean
age at T2DM diagnosis was 56.09 years and the
mean HbA1c at baseline was 8.34%. SUs were
the most common second-line treatment pre-
scribed in addition to metformin (49.11%),
followed by DPP4i (41.58%), SGLT2i (6.83%)
and TZDs (2.48%). Individuals’ characteristics at
baseline varied by drug class. For example,
people initiated on an SGLT2i were relatively
younger with fewer comorbidities than people
initiated on other second-line therapies, but
with heavier body weight and greater body mass
index (BMI).
Factors Associated with Drug Response
At 12 months post-baseline (Fig. 1), SGLT2i
appeared to be most potent in relatively
younger males with lower BMI and high dias-
tolic blood pressure (DBP). SUs, however,
demonstrated the greatest improvement in rel-
atively older males with lower BMI and lower
estimated glomerular filtration (eGFR) rate.
Males with higher DBP and SBP but lower eGFR
benefitted most from DPP4i. However, only the
trends in patient age for SGLT2i and SUs were
statistically significant. TZDs gave consistent
results in all individuals irrespective of baseline
characteristics, with baseline HbA1c being the
only predictive factor.
Change in HbA1c from Baseline
Mean HbA1c at baseline was similar among
people receiving a SU, DPP4i, TZD or SGLT2i at
second-line (8.40%, 8.26%, 8.37% and 8.38%
respectively) (Table 2). At 6 and 12 months,
over half of people who were still on therapy
achieved a HbA1c \ 7.5% in each drug class.
This ranged from 58.90% for SGLT2i to 70.14%
for SUs at 6 months and from 60.56% for SUs to
67.44% for SGLT2i at 12 months. However, as
SGLT2i, TZD and SU therapies were initiated in
people with incrementally higher baseline
HbA1c, there were greater improvements in
HbA1c for these individuals over the study
period (Table S1). For example, in people still on
therapy at 12 months, there was a mean
reduction of 1.08% (12 mmol/mol), 0.99%
(11 mmol/mol) and 0.97% (10 mmol/mol) for
individuals who had received a SGLT2i, TZD or
SU, respectively, compared with mean reduc-
tion of 0.74% (8 mmol/mol) for individuals
who had received a DPP4i (Table 2). The distri-
butions of change in HbA1c from baseline at 6
and 12 months were similar across the four drug
classes (Figure S2).
After variable reduction was performed, the
6- and 12-month models were fitted to each
drug class. Baseline HbA1c, age, BMI, systolic
blood pressure (SBP) and sex were present
within both the 6- and 12-month models.
Triglycerides were present in the 6-month
model only; total cholesterol and ethnicity were
present in the 12-month model only. After
adjusting for these demographic and baseline
clinical characteristics, regardless of drug class,
people with higher HbA1c at baseline and
remaining on therapy achieved greater
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Table 1 Baseline patient demographic and clinical characteristics
Characteristic Overall
(N = 7170)
SU (N = 3521) DPP4i
(N = 2981)
TZD
(N = 178)
SGLT2i
(N = 490)
Age in years, mean (SD)
At T2DM diagnosis 56.09 (10.91) 56.79 (11.23) 56.01 (10.54) 54.87 (12.10) 52.04 (9.33)
At second-line therapy
initiation
60.57 (11.53) 61.19 (11.83) 60.61 (11.19) 59.44 (12.86) 56.25 (9.80)
Gender, n (%)
Male 4280 (59.69%) 2100 (59.64%) 1789 (60.01%) 116 (65.17%) 275 (56.12%)
Ethnicity, n (%)
White 1137 (15.86%) 597 (16.96%) 447 (14.99%) 38 (21.35%) 55 (11.22%)
Other 91 (1.27%) 50 (1.42%) 35 (1.17%) \ 5* \ 5*
Not recorded 5942 (82.87%) 2874 (81.62%) 2499 (83.83%) 137 (76.97%) 432 (88.16%)
Smoking status, n (%)
Current smoker 1095 (15.27%) 559 (15.88%) 425 (14.26%) 34 (19.10%) 77 (15.71%)
Former smoker 2562 (35.73%) 1266 (35.96%) 1073 (35.99%) 53 (29.78%) 170 (34.69%)
Passive smoker 14 (0.20%) \ 5* 10 (0.34%) 0 (0.00%) \ 5*
Non-smoker 3453 (48.16%) 1669 (47.40%) 1456 (48.84%) 90 (50.56%) 238 (48.57%)
Not recorded 46 (0.64%) 25 (0.71%) 17 (0.57%) \ 5* \ 5*
Duration of T2DM in years, mean (SD)
At second-line therapy
initiation
4.47 (2.98) 4.41 (2.98) 4.59 (2.96) 4.57 (3.18) 4.21 (3.01)
Clinical measurements (latest value B 6 months prior to second-line initiation)
Height (m)
n (%) 1708 (23.82%) 852 (24.20%) 733 (24.59%) 34 (19.10%) 89 (18.16%)
Mean (SD) 1.69 (0.10) 1.69 (0.10) 1.69 (0.10) 1.70 (0.10) 1.71 (0.10)
Weight (kg)
n (%) 5927 (82.66%) 2858 (81.17%) 2504 (84.00%) 142 (79.78%) 423 (86.33%)
Mean (SD) 95.55 (20.68) 92.65 (19.86) 96.91 (20.75) 92.25 (20.29) 108.16 (20.37)
BMI (kg/m2)
n (%) 5893 (82.19%) 2840 (80.66%) 2489 (83.50%) 142 (79.78%) 422 (86.12%)
Mean (SD) 33.10 (6.33) 32.19 (6.10) 33.50 (6.27) 32.08 (5.92) 37.14 (6.47)
HbA1c [%]
n (%) 7170 (100.00%) 3521 (100.00%) 2981 (100.00%) 178 (100.00%) 490 (100.00%)
Mean (SD) 8.34 (0.78) 8.40 (0.78) 8.26 (0.76) 8.37 (0.81) 8.38 (0.80)
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improvements in glucose control at 6 and
12 months post-baseline (Fig. 2). At 12 months,
SUs demonstrated a loss in potency at higher
HbA1c levels, DPP4i and TZDs remained
equipotent over the time period, whereas
SGLT2i demonstrated a greater effect on gly-
caemic control in those with highest HbA1c
baseline levels (Fig. 2). For people with T2DM
Table 1 continued
Characteristic Overall
(N = 7170)
SU (N = 3521) DPP4i
(N = 2981)
TZD
(N = 178)
SGLT2i
(N = 490)
DBP (mmHg)
n (%) 6513 (90.84%) 3163 (89.83%) 2747 (92.15%) 158 (88.76%) 445 (90.82%)
Mean (SD) 78.21 (8.94) 78.12 (9.08) 78.12 (8.80) 77.23 (9.00) 79.80 (8.67)
SBP (mmHg)
n (%) 6513 (90.84%) 3163 (89.83%) 2747 (92.15%) 158 (88.76%) 445 (90.82%)
Mean (SD) 134.18 (13.97) 134.25 (13.92) 134.02 (14.18) 131.87 (11.45) 135.51 (13.79)
eGFR (ml/min/1.73 m2)
n (%) 2580 (35.98%) 1174 (33.34%) 1192 (39.99%) 54 (30.34%) 160 (32.65%)
Mean (SD) 71.77 (14.83) 71.28 (15.09) 71.46 (14.62) 71.63 (14.66) 77.77 (13.13)
TC (mmol/l)
n (%) 6131 (85.51%) 2990 (84.92%) 2569 (86.18%) 154 (86.52%) 418 (85.31%)
Mean (SD) 4.29 (0.98) 4.31 (1.00) 4.26 (0.95) 4.32 (0.96) 4.38 (1.02)
HDL (mmol/l)
n (%) 5642 (78.69%) 2696 (76.57%) 2397 (80.41%) 143 (80.34%) 406 (82.86%)
Mean (SD) 1.16 (0.31) 1.17 (0.32) 1.16 (0.30) 1.11 (0.30) 1.14 (0.27)
LDL (mmol/l)
n (%) 4526 (63.12%) 2102 (59.70%) 1984 (66.55%) 108 (60.67%) 332 (67.76%)
Mean (SD) 2.31 (0.93) 2.28 (0.92) 2.31 (0.91) 2.34 (1.07) 2.51 (0.96)
Triglycerides (mmol/l)
n (%) 5022 (70.04%) 2389 (67.85%) 2173 (72.90%) 118 (66.29%) 342 (69.80%)
Mean (SD) 2.24 (1.33) 2.26 (1.37) 2.19 (1.27) 2.60 (2.01) 2.29 (1.23)
Risk profile, mean (SD)
Charlson comorbidity
index score
3.85 (2.04) 4.01 (2.12) 3.78 (1.98) 3.51 (1.95) 3.29 (1.78)
BMI body mass index, DBP diastolic blood pressure, DPP4i dipeptidyl peptidase 4 inhibitor, eGFR estimated glomerular
filtration rate, HbA1c glycated haemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic
blood pressure, SGLT2i sodium-glucose transport protein 2 inhibitor, SU sulphonylurea, T2DM type 2 diabetes, TC total
cholesterol, TZD thiazolidinedione
*Actual value suppressed because of small numbers
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for whom only modest improvements in HbA1c
were required, i.e. at the point escalation where
treatment is currently recommended (HbA1c
7.5%), there was no clinically meaningful dif-
ference in the benefit achieved by drug class at 6
or 12 months post-baseline. Therefore, predic-
tors of improvement were explored, with the
intention of informing identification of the
right drug for the right person with T2DM.
Treatment Discontinuation
Treatment discontinuation rates were highest
for people with T2DM receiving SGLT2i at sec-
ond line with a greater percentage of people
receiving SGLT2i switching treatment at
6 months (7.55%) and 12 months (11.22%)
compared with people prescribed other second-
line treatments (6 months: 2.25–4.13%;
Table 2 Change in HbA1c at 6 months and 12 months from baseline by drug class
Overall SU DPP4i TZD SGLT2i
At month 0 (latest value B 6 months prior to 2L initiation)
On second-line therapy, N 7170 3521 2981 178 490
With measurement HbA1c [%]
N (%) 7170 (100.00%) 3521 (100.00%) 2981 (100.00%) 178 (100.00%) 490 (100.00%)
HbA1c [%], mean (SD) 8.34 (0.78) 8.40 (0.78) 8.26 (0.76) 8.37 (0.81) 8.38 (0.80)
HbA1c\ 7.5%, N (%) 944 (13.17%) 398 (11.30%) 460 (15.43%) 24 (13.48%) 62 (12.65%)
At month 6a
On therapy, N 6238 (87.00%) 3103 (88.13%) 2573 (86.31%) 155 (87.08%) 407 (83.06%)
With measurement
N (%) 4803 (77.00%) 2371 (76.41%) 2008 (78.04%) 115 (74.19%) 309 (75.92%)
HbA1c [%], mean (SD) 7.33 (0.97) 7.25 (1.01) 7.42 (0.93) 7.44 (0.91) 7.38 (0.79)
HbA1c\ 7.5%, N (%) 3177 (66.15%) 1663 (70.14%) 1261 (62.80%) 71 (61.74%) 182 (58.90%)
Change at 6 months (for patients with recorded values at initiation and month 6)
Mean 4 HbA1c [%], (SD) - 1.01 (0.98) - 1.18 (1.05) - 0.81 (0.89) - 0.98 (0.82) - 1.03 (0.86)
At month 12b
On therapy, N 5402 (75.34%) 2750 (78.10%) 2166 (72.66%) 138 (77.53%) 348 (71.02%)
With measurement
N (%) 4068 (75.31%) 2059 (74.87%) 1645 (75.95%) 106 (76.81%) 258 (74.14%)
HbA1c [%], mean (SD) 7.44 (1.07) 7.46 (1.12) 7.43 (1.02) 7.44 (1.20) 7.29 (0.88)
HbA1c\ 7.5%, N (%) 2,522 (62.00%) 1,247 (60.56%) 1,034 (62.86%) 67 (63.21%) 174 (67.44%)
Change at 12 months (for patients with recorded values at initiation and month 12)
Mean 4 HbA1c [%], (SD) - 0.88 (1.07) - 0.97 (1.11) - 0.74 (1.00) - 0.99 (1.23) - 1.08 (0.98)
DPP4i dipeptidyl peptidase 4 inhibitor, HbA1 glycated haemoglobin, SD standard deviation, SGLT2i sodium-glucose
transport protein 2 inhibitor, SU sulphonylurea, TZD thiazolidinedione
a Closest value to month 6, ± 3 months)
b Closest value to month 12, ± 3 months)
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12 months: 5.28–7.98%). More people pre-
scribed DPP4i or SGLT2i at second-line required
escalation of treatment (addition of another
drug) (8.45% and 6.73% by month 12 respec-
tively) compared with those receiving SUs or
TZDs (2.78% and 3.93% respectively) (Table S2).
Adverse Events
Given the limitations of database analysis,
adverse events reported in this study may not be
directly attributable to the drugs of interest
(Table S3). Fracture risk was highest with
SGLT2i and SUs. Retinopathy was higher than
previously reported in those treated with TZDs
at 252.87 events per 1000 patient years [31].
Unexpectedly, congestive cardiac failure was
notably lower in people treated with TZDs,
probably reflecting a selection bias in this real-
world data set.
Treatment Adherence
The percentage of people who were non-ad-
herent to second-line therapy was similar for
SUs, SGLT2i and TZDs, with 5.77%, 5.10% and
5.06% of people in each drug class having an
MPR\80%. In comparison, fewer people pre-
scribed DPP4i were non-adherent as 3.84% had
an MPR\80%. At 12 months after baseline,
MPR C 80% was associated with greater
improvement in HbA1c compared with MPR\
80% for all drug classes (Figure S3). This was
most noticeable for treatment with SUs, SGLT2i
and TZDs.
DISCUSSION
The results of this study demonstrate, using a
real-world population, that similar percentages
of people who received each of the four classes
of second-line OHAs achieved the recom-
mended HbA1c target of\7.5%
(58 mmol/mol). This study also demonstrated
that there are trends in HbA1c response associ-
ated with different phenotypes. All second-line
OHAs appeared to be well tolerated with low
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rates of non-adherence. Across all drug classes,
people with higher MPR (C 80%) also had
greater improvements in HbA1c at 12 months
post-baseline, especially those on drugs other
than DPP4i.
With a range of second-line therapy options
available after metformin monotherapy for
T2DM, and lack of definitive clinical guidance
on the most appropriate drug to prescribe,
clinicians may be uncertain regarding the opti-
mal treatment for any given patient. Paradoxi-
cally, the lack of certainty has resulted in a rise
in the HbA1c at which second-line therapies are
introduced [32]. Whereas the glycaemic effects
of T2DM second-line drugs on HbA1c levels
have been examined in clinical studies, the
clinical implication of these studies is limited by
the small study numbers and homogeneity of
the study populations. Meta-analyses of clinical
trials may be better powered and more gener-
alisable, but they are limited by publication
bias, small study effects and limited degree of
heterogeneity. This study is the first to provide
real-world evidence comparing the relative
effectiveness of SUs, TZDs, DPP4i and SGLT2i
after metformin for glycaemic control accord-
ing to a person’s phenotypic characteristics at
second-line initiation. It is important to note
that we deliberately excluded populations in
whom certain agents had a demonstrated ben-
efit in CVOTs (such as proven atherosclerosis or
heart failure) to focus solely on the population
for which there is prescriptive uncertainty. The
study found very little difference in the gly-
caemic effects of these OHAs, reflecting findings
reported in recent systematic reviews and meta-
analyses [27, 33]. However, the results demon-
strated that for certain sub-groups, a particular
drug class may be more beneficial.
The results of this study suggest that SGLT2i
may be an appropriate treatment choice at sec-
ond line for males with T2DM who are rela-
tively young, with lower BMI and higher DBP,
as individuals with these characteristics
achieved a greater improvement in HbA1c
compared with individuals without such char-
acteristics. The data further demonstrated that
relatively older males with lower BMI and lower
eGFR are likely to benefit from SUs at second-
line, potentially an effect of accumulation due
to renal failure and insulin resistance burn out
that occurs with ageing as sarcopaenia ensues.
While the data appeared to display associations
between these phenotypic characteristics and
HbA1c improvement, only the trends in age for
SGLT2i and SUs were statistically significant. In
a randomised controlled trial setting, females
with T2DM and relatively high BMI achieved
better response with TZDs but the same effect
was not found using data from real-world clin-
ical practice [32]. This may potentially be due to
the relatively small number of people on TZDs
in this study. The effect of DPP4i on glycaemic
control was consistent irrespective of baseline
characteristics; therefore, DPP4i may be used for
people with T2DM who do not fit the charac-
teristics for another class and therefore would
not be expected to accrue as much benefit from
alternative agents.
A similar real-world evidence study, the
international EDGE (Effectiveness of Diabetes
control with vildaGliptin and vildagliptin/
mEtformin) study, prospectively compared the
efficacy and safety of the DPP4i vildagliptin
with other OHAs in people with T2DM not
adequately controlled on monotherapy. The
results demonstrated that in a real-world set-
ting, vildagliptin as a second drug can lower
HbA1c without well-recognised side effects
more frequently than comparator OHAs [34]. It
has been hypothesised that the reason for these
differences in the EDGE trial, where the pre-
dominant comparator was SUs, was differences
in adherence. It has been suggested that par-
ticipants in that particular study who experi-
enced a hypoglycaemic episode would be more
likely to discontinue or have a lower adherence
to therapy than their counterparts who did not
experience such adverse events on DPP4i. Our
population used more modern SUs (with a
lower risk of hypoglycaemia), which may be
why this difference was not consistently
observed, although slightly fewer people on
DPP4i compared with other drug classes had a
MPR\80%. An alternative explanation may be
the difference between prescribing strategies in
clinical trials, where the optimum dose of agent
is commenced within a few weeks, and clinical
practice, where doses are escalated slowly
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dependent on response and observed
hypoglycaemia.
In this study, there is the possibility of con-
founding by indication as treatments were
selected based on clinical judgement according
to specific patient characteristics. This non-
random selection resulted in differences
between the baseline characteristics of the
treatment groups, although multivariate
regression was undertaken to adjust for these
differences. Additionally, not all relevant con-
founding factors are captured in CPRD, and the
analyses may have been affected by the quality
and completeness of original data entry. How-
ever, key factors such as age and comorbidities
that have previously been identified [30, 32]
were accounted for in this study. Further
potential limitations of this study include
medical records showing prescriptions rather
than medication use, and therefore analyses
assume patient adherence to their medication,
which in turn is likely to over-estimate MPR.
The strict study inclusion criteria included
individuals in the analysis if they received one
repeat prescription and consequently people
who discontinued therapy after the first pre-
scription (for example, because of candidiasis
whilst receiving an SGLT2i, hypoglycaemia
when receiving SU therapy or an exacerbation
of their heart failure on a TZD) were not quan-
tified in this analysis. Regarding the analysis of
AEs, with CPRD data it is difficult to determine
truly incident events because of the nature of
the coding (ongoing or historical events may be
incorrectly recorded as new events). Incident
cases within the study period have been inclu-
ded, but it should be noted that this may
include pre-existing conditions.
In summary, this study has identified phe-
notypic characteristics that have the potential
to influence individual treatment response.
Accounting for these characteristics in clinical
treatment decisions may improve therapy
selection and the outcomes of individual
patients. Additional studies are needed to verify
the predictive value of these factors and to
determine their clinical utility.
CONCLUSION
The evidence from this study can potentially be
used to support better targeting of second-line
T2DM therapy. The choice of which drug to
offer after metformin should be based on the
individual person’s phenotypic characteristics
(including gender, age, BMI, eGFR and duration
of T2DM), considering their treatment goals,
extent of hyperglycaemia, comorbidities and
the beneficial and adverse effects of each class of
drug to select the right drug for the right
patient.
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